120
Participants
Start Date
June 1, 2025
Primary Completion Date
June 1, 2030
Study Completion Date
June 1, 2031
GLP-1 receptor agonist
Participants prescribed a GLP-1 receptor agonist (semaglutide) by their physician will be enrolled in this arm of the study. All participants will receive study provided calcium \& vitamin D supplement to support bone health and to reduce this as a confounding factor in overall outcomes
Lifestyle Management
Participants receiving usual lifestyle interventions will be enrolled in this arm of the study. All participants will receive study provided calcium \& vitamin D supplement to support bone health and to reduce this as a confounding factor in overall outcomes
University of Virginia Medical Center, Charlottesville
National Institutes of Health (NIH)
NIH
University of Virginia
OTHER